COMPARE AND CONTRAST THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1RAS)

Course overview

GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) ARE A CLASS OF MEDICATIONS USED TO TREAT ADULT TYPE 2 DIABETES AND OBESITY. THEY ARE IN THE DRUG CLASS OF INCRETIN MIMETICS. GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA, GLP-1DAS, INCRETIN MIMETICS, OR GLP-1 ANALOGS) ARE A CLASS OF MEDICATIONS UTILIZED IN TREATING TYPE 2 DIABETES AND OBESITY. CLINICAL TRIALS SHOW THE SUPERIORITY OF GLP-1RA TO OTHER ANTIHYPERGLYCEMIC DRUGS IN IMPROVING GLYCEMIC EFFICACY, REDUCING WEIGHT AND BLOOD PRESSURE, AND HAVING A CARDIOPROTECTIVE EFFECT, ALL WITHOUT THE RISK OF HYPOGLYCEMIA. THESE DRUGS HAVE TRANSFORMED THE GUIDELINES FOR THE MANAGEMENT OF DIABETES.THIS ACTIVITY REVIEWS THE INDICATIONS, MECHANISM OF ACTION, ADVERSE EFFECTS, AND OTHER CRITICAL ELEMENTS OF THESE DRUGS. IN ADDITION, THIS ACTIVITY HIGHLIGHTS THE COMPARISON BETWEEN DIFFERENT GLP-1 RECEPTOR AGONISTS WITHIN THE SAME CLASS BASED ON PHARMACOKINETICS, DURATION OF ACTION, EFFICACY, AND SAFETY PROFILE PERTINENT TO THE INTERPROFESSIONAL HEALTHCARE TEAM IN USING THIS CLASS OF MEDICATIONS FOR TREATING DIABETES, OBESITY, AND THEIR SEQUELAE.